Abstract 349 Sandra Horning, Stanford University Medical Center
It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therapy in patients with advanced follicular lymphoma. However, the use of rituximab maintenance, after induction therapy, brought clear benefits among patients in the study.
Reporting from:
American Society of Hematology Meeting,
Philadelphia, December 6-10, 2002
Scientific Editors:
George Canellos, Dana-Farber Cancer Institute, Boston
Anton Hagenbeek, University of Utrecht
John Goldman,
Post a comment